The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback